Literatur
- 1
American Diabetes Association .
Standards of medical care in diabetes.
Diabetes Care.
2005;
28
S4-S36
- 2
Apitz R, Winter S F.
Potenziale und Ansätze der Prävention: aktuelle Entwicklungen in Deutschland.
Internist.
2004;
45
139-147
- 3
Assmann G, Corsini A, Davignon J, Grundy S M, Libby P, März W. et al .
Cholesterol-lowering with statins: are they all the same?.
Drugs of Today.
2004;
40
555-561
- 4
Burr D, Doss H, Cooke G E, Goldschmidt-Clermont P J.
A meta-analysis of studies on the association of the platelet PlA polymorphism of
glycoprotein IIIa and risk of coronary heart disease.
Stat Med.
2003;
22
1741-1760
- 5
Burzotta F, Paciaroni K, De S V, Crea F, Maseri A, Leone G, Andreotti F.
G20210A prothrombin gene polymorphism and coronary ischaemic syndromes: a phenotype-specific
meta-analysis of 12 034 subjects.
Heart.
2004;
90
82-86
- 6
Cannon C P, Braunwald E. et al .
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med.
2004;
350
1495-1504
- 7
Casas J P, Bautista L E, Humphries S E, Hingorani A D.
Endothelial nitric oxide synthase genotype and ischemic heart disease.
Circulation.
2004;
109
1359-1365
- 8
Colhoun H M, Betteridge D J, Durrington P N, Hitman G A. et al .
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes
in the Collaborative Atorvastatin Diabetes Study (CARDS).
Lancet.
2004;
364
685-696
- 9
Collins R. et al .
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people
with diabetes.
Lancet.
2003;
361
2005-2016
- 10
Di Castelnuovo A, de Gaetano G, Donati M B, Iacoviello L.
Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis.
Thromb Haemost.
2001;
85
626-633
- 11
Ezzati M.
How can cross-country research on health risks strengthen interventions? Lessons from
INTERHEART.
Lancet.
2004;
364
912-914
- 12
Godsland I F.
Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein
(a) concentrations: analysis of studies published from 1974 - 2000.
Fertil Steril.
2001;
75
898-915
- 13
Grundy S M, Cleeman J I, Merz C N, Brewer H B, Clark L T, Hunninghake D B, Pasternak R C,
Smith S C, Stone N J.
Implications of recent clinical trials for the National Cholesterol Education Program
Adult Treatment Panel III guidelines.
Circulation.
2004;
110
227-239
- 14
Heart Protection Study Collaborative Group .
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536
high-risk individuals: a randomised placebo-controlled trial.
Lancet.
2002;
360
7-22
- 15
Helgadottir A. et al .
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction
and stroke.
Nat Genet.
2004;
36
233-239
- 16
Humphries S E, Ridker P M, Talmud P J.
Genetic testing for cardiovascular disease susceptibility: a useful clinical management
tool or possible misinformation?.
Arterioscler Thromb Vasc Biol.
2004;
24
628-636
- 17
Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati M B.
The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction:
a meta-analysis.
Thromb Haemost.
1998;
80
1029-1030
- 18
Jones P, Kafonek S, Laurora I, Hunninghake D.
Comparative dose efficacy study of Atorvastatin versus Simvastatin, Pravastatin, Lovastatin,
and Fluvastatin in patients with hypercholesterolemia (The CURVES study).
Am J Cardiol.
1998;
81
582-587
- 19
Jones P H, Davidson M H, Stein E A, Bays H E, Mckenney J M, Miller E, Cain V A, Blasetto J W.
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin,
and pravastatin across doses (STELLAR* Trial).
Am J Cardiol.
2003;
92
152-160
- 20
Keavney B, Parish S, Palmer A, Clark S, Youngman L, Danesh J, McKenzie C, Delepine M,
Lathrop M, Peto R, Collins R.
Large-scale evidence that the cardiotoxicity of smoking is not significantly modified
by the apolipoprotein E epsilon2/epsilon3/epsilon4 genotype.
Lancet.
2003;
361
396-398
- 21
Kim R J, Becker R C.
Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate
reductase C677T mutations and events of the arterial circulatory system.
Am Heart J.
2003;
146
948-957
- 22
Klerk M, Verhoef P, Clarke R, Blom H J, Kok F J, Schouten E G.
MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis.
JAMA.
2002;
288
2023-2031
- 23
Kuch B, Bolte H D, Hoermann A, Meisinger C, Loewel H.
What is the real hospital mortality from acute myocardial infarction? Epidemiological
vs clinical view.
Eur Heart J.
2002;
23
714-720
- 24
LaRosa J C, Grundy S M, Waters D D, Shear C, Barter P, Fruchart J C, Gotto A M, Greten H,
Kastelein J J, Shepherd J, Wenger N K.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
N Engl J Med.
2005;
352
1425-1435
- 25
Law M R, Wald N J, Rudnicka A R.
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart
disease, and stroke: systematic review and meta-analysis.
BMJ.
2003;
326
1423
- 26
Löwel H, Meisinger C, Heier M, Hormann A, Kuch B, Gostomzyk J, Koenig W.
Geschlechtsspezifische Trends von plötzlichem Herztod und akutem Herzinfarkt: Ergebnisse
des bevölkerungsbasierter KORA/MONICA Augsburg Herzinfarkt-Registers 1985 bis 1998.
Dtsch Med Wochenschr.
2002;
127
2311-2316
- 27
Morrison A C, Bray M S, Folsom A R, Boerwinkle E.
ADD1 460W allele associated with cardiovascular disease in hypertensive individuals.
Hypertension.
2002;
39
1053-1057
- 28
Pearson T A, Mensah G A, Alexander R W, Anderson J L, Cannon R O, Criqui M, Fadl Y Y,
Fortmann S P, Hong Y, Myers G L. et al .
Markers of inflammation and cardiovascular disease: application to clinical and public
health practice: A statement for healthcare professionals from the Centers for Disease
Control and Prevention and the American Heart Association.
Circulation.
2003;
107
499-511
- 29
Ridker P M, Cannon C P, Morrow D, Rifai N, Rose L M, McCabe C H, Pfeffer M A, Braunwald E.
C-reactive protein levels and outcomes after statin therapy.
N Engl J Med.
2005;
352
20-28
- 30
Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed W A, Blackett K N, Sitthi-amorn C,
Sato H, Yusuf S.
Association of psychosocial risk factors with risk of acute myocardial infarction
in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study).
Lancet.
2004;
364
953-962
- 31
Sciarrone M T, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, Cusi D.
ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy.
Hypertension.
2003;
41
398-403
- 32
Shlipak M G, Simon J A, Vittinghoff E, Lin F, Barrett-Connor E, Knopp R H, Levy R I,
Hulley S B.
Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease
events after menopause.
JAMA.
2000;
283
1845-1852
- 33
Song Y, Stampfer M J, Liu S.
Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease.
Ann Intern Med.
2004;
141
137-147
- 34
Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M.
DACH-LIGA homocystein (German, Austrian and Swiss Homocysteine Society): consensus
paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular
and thrombotic diseases: guidelines and recommendations.
Clin Chem Lab Med.
2003;
41
1392-1403
- 35
Toole J F, Malinow M R, Chambless L E, Spence J D, Pettigrew L C, Howard V J, Sides E G,
Wang C H, Stampfer M.
Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke,
myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP)
randomized controlled trial.
JAMA.
2004;
291
565-575
- 36
Wald D S, Law M, Morris J K.
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.
BMJ.
2002;
325
1202-1208
- 37
Whitworth J A, Chalmers J.
World health organisation-international society of hypertension (WHO/ISH) hypertension
guidelines.
Clin Exp Hypertens.
2004;
26
747-752
- 38
Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M,
Yokota M.
Prediction of the risk of myocardial infarction from polymorphisms in candidate genes.
N Engl J Med.
2002;
347
1916-1923
- 39
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A. et al
.
Effect of potentially modifiable risk factors associated with myocardial infarction
in 52 countries (the INTERHEART study).
Lancet.
2004;
364
937-952
- 40
Zee R Y, Cook N R, Cheng S, Reynolds R, Erlich H A, Lindpaintner K, Ridker P M.
Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke:
a population-based, prospective genetic analysis.
Hum Mol Genet.
2004;
13
389-396
- 41
Helgadottir A, Gretarsdottir S, St Clair D, Manolescu A, Cheung J, Thorleifsson G,
Pasdar A, Grant S F, Whalley L J, Hakonarson H, Thorsteinsdottir U, Kong A, Gulcher J,
Stefansson K, MacLeod M J.
Association between the gene encoding 5-lipoxygenase-activating protein and stroke
replicated in a Scottish population.
Am J Hum Gente .
2005;
76
505-509
- 42
Lohmussaar E, Gschwendtner A, Mueller J C, Org T, Wichmann E, Hamann G, Meitinger T,
Dichgans M.
ALOX5AP gene and the PDE4D gene in a central European population of stroke patients.
Stroke.
2005;
36
731-736
1 Teile dieser Arbeit wurden auf dem 29. Interdisziplinären Forum der Bundesärztekammer
„Fortschritt und Fortbildung in der Medizin” vom 6. bis 8. Januar 2005 in Berlin von
G.A. vorgetragen und werden im Berichtband des Forums veröffentlicht
Prof. Dr. Gerd Assmann
Leibniz-Institut für Arterioskleroseforschung
Domagkstraße 3
48149 Münster
Phone: 0251/8347222
Fax: 0251/8347225
Email: assmann@uni-muenster.de
